Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Mehr anzeigen
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in patients with triple-negative breast...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.71 | -50 | 1.42 | 1.455 | 0.6888 | 2224202 | 1.36285353 | CS |
| 4 | -1.6 | -69.2640692641 | 2.31 | 2.31 | 0.6888 | 1821355 | 1.54789141 | CS |
| 12 | -1.41 | -66.5094339623 | 2.12 | 2.83 | 0.6888 | 1305589 | 1.98874788 | CS |
| 26 | -1.21 | -63.0208333333 | 1.92 | 2.83 | 0.6888 | 1195467 | 1.89582971 | CS |
| 52 | -2.51 | -77.950310559 | 3.22 | 6.2801 | 0.6888 | 1571663 | 2.96879869 | CS |
| 156 | -5.57 | -88.6942675159 | 6.28 | 9.62 | 0.6888 | 2085775 | 3.38248253 | CS |
| 260 | -4.8 | -87.1143375681 | 5.51 | 29.09 | 0.6888 | 1638600 | 6.32249378 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
